Articles by Anna Rose Welch
-
Will It Be Biologics Business As Usual In 2021, Or Will Biosimilars Mean Business?
1/20/2021
In this fourth installment of the Editorial Board 2021 Outlook, it's clear that stakeholders are relying more heavily on biosimilars and that it’s more important than ever for biosimilar companies to keep carrying the torch for more competition, cost-savings, value, and responsible pricing.
-
The Biosimilar Toolbox: How To Ratchet Up Biosimilar Competition In 2021
1/6/2021
As you’ll read in the following responses, increased competition in 2021 is on the minds of many. How that competition unfolds has yet to be determined. But if one thing is clear, it’s that the industry has many exciting tools at its disposal to bolster biosimilar competition in 2021.
-
The Top 5 Biosimilar Developments Of 2020
12/30/2020
Though 2020 felt like an endless descent into Dante’s Nine Circles of Hell, I wanted to end the year as I typically do: with a column highlighting the most important and positive biosimilar developments from the past 12 months.
-
Will These Big Biosimilar Questions Be Answered In 2021?
12/23/2020
Biosimilar Development is back with the highly anticipated second installment of its Editorial Board 2021 Outlook series! Here, the experts address the biggest questions they have going into 2021, as well as some of the events, policies, and corporate strategies they hope will help answer these questions.
-
The Past, Present, & Future of Biosimilar Manufacturing
10/14/2020
A recent publication entitled "Approval of Biosimilars: A Review of Unsuccessful Regulatory Filings" revealed the most common manufacturing issues the FDA and EMA flagged in biosimilar applications. Here, the lead author discusses his findings from the past, current manufacturing challenges, and which technologies could be most impactful for the future biosimilar industry.
-
Biosimilar Industry Advancements To Watch In 2020
1/8/2020
Multi-biosimilar competition in the U.S. oncology space, as well as the FDA’s regulatory progress toward a more competitive insulin market were popular topics among the whole group. But these are hardly the only big events to note in this progressing industry.
-
The Top 7 Biosimilar Developments of 2019
12/30/2019
I normally only do the top five developments for the biosimilar industry in this annual column. But it turned out, upon reflection, that 2019 was an even more eventful year than it may have seemed as we were making our way through. So, you’re getting a whopping seven this year.
-
FDA's Woodcock: Biosimilar Development Promotes Future Of Better Biologics
9/30/2019
While some regulators may express skepticism that we’ll see major changes to the clinical component of the biosimilar development pathway, Woodcock’s DIA keynote exemplified what I found to be a strikingly different attitude about the future possibilities for biosimilar development.
-
A Second Reformation: Returning Biosimilar Regulations To Scientific Roots
8/14/2019
In light of BioApproval's Chris Webster’s recent publication and future presentation at the upcoming DIA Biosimilars conference, I spoke with him to learn more about the "Confirmation of Sufficient Likeness" approach and the scientific evidence that has informed this proposed biosimilar regulatory paradigm shift away from Totality of Evidence.
-
Cutting Through The Noise: The Bright Side Of Biosimilar Progress
7/29/2019
Because negative news and opinions seem to create greater waves, I thought I would take stock of the positive news that may not have come over your desks or (more realistically) cellphones in the past few weeks. While it’s easy to get bogged down by negative speculation, there’s progress being made and companies and experts fighting daily to keep this industry moving forward, even if it feels glacial.